Syros Goes For Reboot With New Investors And Leukemia Licensing
Bain Capital Leads $90.5m Investment
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.